Imgatuzumab

Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 16, 2022
Senior, MBA, Company, Master of Science, Risk, Nasdaq, Doctor of Philosophy, CNTA, Patient, Imgatuzumab, Poster, Business development, Cash, Secondary research, Chief medical informatics officer, COVID-19, Autoimmune disease, Patent, FDA, Research, IND, Industry, Omicron, Program, ADPKD, Safety, ASCO, Haemophilia B, Maintenance, EGFR, Pizzicato, PD, Administration, Acquisition, SEC, Research and development, MD, AATD, GLOBE, Online gambling, Pharmaceutical industry, Vaccine, Animal, Risk management, Lixivaptan, Haemophilia, Development, Delta

BOSTON and LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today reported financial results for the first quarter ended March 31, 2022 and provided business updates.

Key Points: 
  • In the near term, we are excited to share initial preclinical data for LB101, our PD-L1xCD47 LockBody at ASCO 2022 in June.
  • Lixivaptan: Commenced dosing in the pivotal Phase 3 clinical trial (ACTION Study) evaluating lixivaptan as a potential treatment for ADPKD.
  • LB101 in Solid Tumors: Preclinical data for LB101, a PD-L1xCD47 LockBody, will be presented in a poster at ASCO 2022 on June 5, 2022.
  • Centessa Pharmaceuticals plc (Centessa) is a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients.

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 30, 2022
BDCA2, Risk, Polycystic kidney disease, Pizzicato, SEC, Research, Mab, EGFR, MD, ASCO, Nasdaq, AATD, GLOBE, Quarter, Autoimmune disease, Autosome, ADPKD, Haemophilia A, Successor, Secondary research, Omicron, Industry, NT1, CNTA, Neoplasm, Chief medical informatics officer, Toxicity, Haemophilia B, Patent, Hypertensive emergency, Part, Doctor of Philosophy, Program, CD3, CVR Partners, Alpha-1 antitrypsin deficiency, Pulmonary hypertension, Narcolepsy, FDA, Patient, NFL Player's Association Financial Registration Program, Administration, Company, BMP9, PAH, D, Imgatuzumab, Oral, CD47, Cash, IND, Safety, Master of Science, COVID-19, Nasal administration, Maintenance, Research and development, Acquisition, Pharmaceutical industry, Renewable energy, Medicine, Risk management, Animal, Lixivaptan, Delta, Development, Haemophilia

R&D Expenses: $41.5 million for the Company for the quarter ended December 31, 2021, $95.7 million for the Successor for 2021.

Key Points: 
  • R&D Expenses: $41.5 million for the Company for the quarter ended December 31, 2021, $95.7 million for the Successor for 2021.
  • General & Administrative Expenses: $13.0 million for the Company for the quarter ended December 31, 2021, $42.9 million for the Successor for 2021.
  • Centessa Pharmaceuticals plc (Centessa) is a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients.
  • We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law.

Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates

Retrieved on: 
Monday, August 16, 2021
ADSS, Audit committee, CSCC, Form, American depositary receipt, Polycystic kidney disease, HA, Research, Director, Organization, Growth, G&A, Contingent value rights, APC, Safety, Industry, CVR, Review, Imgatuzumab, Administration, Chairperson, Tolvaptan, Company, Risk, SEC, Genotype, Neuroscience, ADS, ADCC, Liver, COVID-19, Alpha-1 antitrypsin deficiency, AATD, Board, Exercise, IPO, Nephrology, Hematology, Mab, CNTA, ADCP, Serum, EGFR, Probability, HB, GLOBE, Research and development, Acquisition, Patient, Secondary research, General Administration of Sport of China, ADPKD, Nasdaq, Appointment, R, Autosome, Management, Pharmaceutical industry, Fine chemical, Risk management

CAMBRIDGE, Mass. and LONDON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today reported financial results for the quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.

Key Points: 
  • and LONDON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today reported financial results for the quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
  • $379.5 Million Initial Public Offering (IPO) Successfully Completed: In the second quarter, Centessa closed its initial public offering of 16,500,000 American Depositary Shares (ADSs).
  • The gross proceeds to Centessa from its IPO, before deducting underwriting discounts, commissions and other estimated offering expenses, totaled an aggregate of $379.5 million.
  • The Phase 2a has completed dosing and the Company anticipates sharing topline results in the third quarter of 2021.